

Combined whooping cough vaccine

Numbers for adolescents and adults relating to potential exposure to whooping cough bacteria.

	100 people without combined booster vaccine exposed to whooping cough bacteria	100 people with combined booster vaccine exposed to whooping cough bacteria
Benefits*/**		
How many people get whooping cough?	45-79	3-12
How many people suffer from coughing lasting longer than three weeks due to whooping cough?	36-77	2-12
How many people suffer from vomiting after coughing due to whooping cough?	8-51	1-8

	100 people with tetanus and diphtheria vaccination (TD)	100 people with tetanus, diphtheria and pertussis vaccination (Tdap)
Harms***		
How many people had a high temperature (over 37.5°C)?	about 5-33 in each group	
How many people experienced headache?	about 32-44 in each group	
How many people experienced fatigue?	about 26-41 in each group	

*Receiving a combined booster vaccine against pertussis also prevents tetanus and diphtheria. **Numbers given under benefits are based on model calculations.

***Redness, pain, or swelling as local side effects around the injection site are possible within 48 hours after vaccination for both types of vaccines.

Short summary: The combined whooping cough booster vaccine may prevent getting pertussis after contact with whooping cough bacteria. Redness, pain, or swelling around the injection site are possible. Severe reactions to the vaccination are unknown.

Sources: [1] McIntyre et al. *Vaccine* 2009;27(7):1062-6. [2] Forster et al. In: Berner (ed.) DGPI Handbuch Infektionen bei Kindern und Jugendlichen: Thieme 2013. [3] Doerr & Thraenhardt. In: Kark & Werner (eds.). Krebs im Alter. Zur Onkologie und Immunologie im höheren Lebensalter: Steinkopff 1988:143-47. [4] Mader & Weigerber In: Mader (ed.). Allgemeinmedizin und Praxis: Anleitung in Diagnostik, Therapie und Betreuung. Facharztprüfung Allgemeinmedizin: Springer 2013. [5] Quast. *Mitt Österr Ges Tropenmed u Parasitologie* 1998;20:157-64. [6] Wirsing von König et al. *Lancet Infect Dis* 2003;2(12):744-50. [7] Turnbull et al. *Vaccine* 2001;19(6):628-36. [8] Van der Wielen et al. *Vaccine* 2000;18(20):2075-82.